Clinical experience with rucaparib after prior PARPi treatment: A subanalysis from the rucaparib access program in Spain by GEICO

MLA

Alfonso Yubero-Esteban, et al. “Clinical Experience with Rucaparib after Prior PARPi Treatment: A Subanalysis from the Rucaparib Access Program in Spain by GEICO.” Journal of Clinical Oncology, vol. 40, June 2022, p. e17598. EBSCOhost, https://doi.org/10.1200/jco.2022.40.16_suppl.e17598.

APA

Alfonso Yubero-Esteban, Piedad Reche-Molina, Carmen Salvador Coloma, Purificación Estévez-García, Luis Manso, Marcos Iglesias Campos, Arantzazu Barquin, Raul Marquez, Ana Santaballa, Julia Calzas, Ana Herrero, Victoria Casado, Julia Madani, Maria Merino, Gloria Marquina, Jesus Alarcon Company, Lydia Gaba, Jose Fuentes Pradera, Antonio Gonzalez Martin, & Maria Luisa Sanchez Lorenzo. (2022). Clinical experience with rucaparib after prior PARPi treatment: A subanalysis from the rucaparib access program in Spain by GEICO. Journal of Clinical Oncology, 40, e17598. https://doi.org/10.1200/jco.2022.40.16_suppl.e17598

Chicago

Alfonso Yubero-Esteban, Piedad Reche-Molina, Carmen Salvador Coloma, Purificación Estévez-García, Luis Manso, Marcos Iglesias Campos, Arantzazu Barquin, et al. 2022. “Clinical Experience with Rucaparib after Prior PARPi Treatment: A Subanalysis from the Rucaparib Access Program in Spain by GEICO.” Journal of Clinical Oncology 40 (June): e17598. doi:10.1200/jco.2022.40.16_suppl.e17598.